01. ProMIS Neurosciences, Inc. (NASDAQ:PMN)
Upside Potential: 750%
Forward Price to Earnings (P/E) Ratio: 5.32
Number of Hedge Fund Holders: 1
Topping our list of seven most undervalued Canadian stocks to buy according to analysts is ProMIS Neurosciences, Inc. (NASDAQ:PMN). It is a clinical-stage biotechnology company based in Toronto, Canada, focused on discovering and developing antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein disorders. The company employs a proprietary discovery platform that utilizes ProMIS and Collective Coordinates algorithms to identify novel targets, known as disease-specific epitopes, on the molecular surface of misfolded proteins. ProMIS’s lead candidate, PMN310, is a monoclonal antibody (mAb) that targets toxic oligomers in Alzheimer’s disease (AD).
In its recent second-quarter earnings report for 2024, ProMIS Neurosciences, Inc. (NASDAQ:PMN) announced several significant developments that underscore the company’s growth potential and progress in advancing its Alzheimer’s program. ProMIS reported positive topline data from its first-in-human Phase 1a clinical trial of PMN310. The trial, which evaluated the safety and tolerability of PMN310, demonstrated that the antibody was generally safe and well-tolerated across multiple dosage levels, with no severe adverse events observed. Importantly, PMN310 showed the ability to penetrate the central nervous system in quantities sufficient to potentially achieve target engagement. This is a critical step as the company prepares to advance to its Phase 1b clinical study in the second half of 2024.
Additionally, ProMIS Neurosciences, Inc. (NASDAQ:PMN) strengthened its financial position by securing up to $122.7 million in private placement financing. This includes an initial upfront investment of $30.3 million and the potential to raise an additional $92.4 million upon achieving certain milestones. These funds will support the continued development of PMN310 and the expansion of its pipeline. The robust financing participation from prominent healthcare specialty funds such as Great Point Partners, LLC, and Armistice Capital reflects investor confidence in ProMIS’s innovative approach to treating Alzheimer’s and other neurodegenerative diseases.
From a financial perspective, ProMIS Neurosciences, Inc. (NASDAQ:PMN) reported a net loss of $2.6 million for the quarter ended June 30, 2024, compared to a loss of $2.3 million in the same period in 2023. The company’s research and development expenses rose to $1.6 million, driven by increased costs related to the PMN310 clinical trial. With a strengthened balance sheet and positive clinical data, ProMIS Neurosciences, Inc. (NASDAQ:PMN) is well-positioned to continue its pursuit of transformative therapies for neurodegenerative diseases, making it a compelling investment opportunity among Canadian biotech stocks.
While we acknowledge the potential of PMN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than PMN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
